Eventide Asset Management LLC Sells 40,704 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Eventide Asset Management LLC lessened its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 29.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 95,781 shares of the company’s stock after selling 40,704 shares during the period. Eventide Asset Management LLC owned 0.33% of Krystal Biotech worth $17,435,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Summit Trail Advisors LLC purchased a new stake in shares of Krystal Biotech during the 3rd quarter valued at about $1,893,000. Swiss National Bank raised its position in shares of Krystal Biotech by 8.0% during the 3rd quarter. Swiss National Bank now owns 39,100 shares of the company’s stock valued at $7,117,000 after buying an additional 2,900 shares in the last quarter. Sei Investments Co. raised its position in shares of Krystal Biotech by 18.9% during the 2nd quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock valued at $7,367,000 after buying an additional 6,363 shares in the last quarter. Shaker Investments LLC OH purchased a new stake in shares of Krystal Biotech during the 3rd quarter valued at about $532,000. Finally, Amalgamated Bank raised its position in shares of Krystal Biotech by 937.9% during the 2nd quarter. Amalgamated Bank now owns 7,577 shares of the company’s stock valued at $1,391,000 after buying an additional 6,847 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This trade represents a 1.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 14.10% of the company’s stock.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $196.91 on Friday. The stock has a market capitalization of $5.66 billion, a price-to-earnings ratio of 111.25 and a beta of 0.82. Krystal Biotech, Inc. has a 1-year low of $99.00 and a 1-year high of $219.34. The business has a fifty day moving average price of $180.23 and a 200-day moving average price of $183.28.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business’s quarterly revenue was up 879.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.67) EPS. On average, equities research analysts anticipate that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Evercore ISI upped their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Stifel Nicolaus increased their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Citigroup raised their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Krystal Biotech currently has a consensus rating of “Buy” and a consensus price target of $202.29.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).